- Home
- MLCI vs IGC Comparison
MLCI vs IGC Comparison
Compare MLCI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLCI | IGC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 32.0M |
| IPO Year | 2026 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MLCI | IGC |
|---|---|---|
| Price | $3.24 | $0.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.44 | N/A |
| AVG Volume (30 Days) | 10.9K | ★ 590.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,566,000.00 | $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $36.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.58 | N/A |
| 52 Week Low | $2.56 | $0.24 |
| 52 Week High | $8.68 | $0.45 |
Technical Indicators
Market Signals| Indicator | MLCI | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 37.31 |
| Support Level | $3.15 | $0.24 |
| Resistance Level | $3.30 | $0.30 |
| Average True Range (ATR) | 0.10 | 0.01 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 68.75 | 21.82 |
Price Performance
Historical ComparisonAbout MLCI Mount Logan Capital Inc.
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.